{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:42Z","timestamp":1792511502895,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.critrevonc.2021.103366","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T19:51:58Z","timestamp":1622058718000},"page":"103366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer"],"prefix":"10.1016","volume":"163","author":[{"given":"Stefano","family":"Fogli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Gianfilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0946-750X","authenticated-orcid":false,"given":"Federico","family":"Cucchiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Del Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Elisei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4414-8934","authenticated-orcid":false,"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2021.103366_bib0005","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1208\/ps010418","article-title":"Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4","volume":"1","author":"Achira","year":"1999","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0010","first-page":"e120","article-title":"Lenvatinib (Lenvima) for thyroid cancer","volume":"57","author":"Anon","year":"2015","journal-title":"Med. Lett. Drugs Ther."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/EJE-19-0763","article-title":"Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: dutch real-life data","volume":"182","author":"Aydemirli","year":"2020","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081736","article-title":"Hypertension caused by lenvatinib and everolimus in the treatment of metastatic renal cell carcinoma","volume":"18","author":"Bendtsen","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0025","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1152\/ajpregu.90502.2008","article-title":"VEGF kinase inhibitors: how do they cause hypertension?","volume":"297","author":"Bhargava","year":"2009","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clgc.2013.11.020","article-title":"A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma","volume":"12","author":"Bitting","year":"2014","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0035","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/bjc.2012.154","article-title":"A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours","volume":"106","author":"Boss","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0045","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctrv.2015.11.003","article-title":"Lenvatinib: role in thyroid cancer and other solid tumors","volume":"42","author":"Cabanillas","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","article-title":"Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer","volume":"46","author":"Cabanillas","year":"2019","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0055","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/cncr.29395","article-title":"A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment","volume":"121","author":"Cabanillas","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0060","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/17425255.2018.1461839","article-title":"Lenvatinib-induced renal failure: two first-time case reports and review of literature","volume":"14","author":"Cavalieri","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0065","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application","volume":"8","author":"Chae","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-0711-5-3","article-title":"Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor","volume":"5","author":"Chen","year":"2006","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0075","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.3748\/wjg.v25.i29.3870","article-title":"Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma","volume":"25","author":"De Mattia","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0080","first-page":"53","article-title":"Drug-induced QT prolongation and sudden death","volume":"107","author":"Del Rosario","year":"2010","journal-title":"Med."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0085","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1248\/bpb.b12-00778","article-title":"Blocking of the human ether-a-go-go-related gene channel by imatinib mesylate","volume":"36","author":"Dong","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchromb.2012.01.004","article-title":"Development and validation of LC-MS\/MS assays for the quantification of E7080 and metabolites in various human biological matrices","volume":"887-888","author":"Dubbelman","year":"2012","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0095","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10637-014-0181-7","article-title":"Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas","volume":"33","author":"Dubbelman","year":"2015","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101966","article-title":"Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs","volume":"84","author":"Fogli","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0105","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12882-018-1074-3","article-title":"Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report","volume":"19","author":"Furuto","year":"2018","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0110","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1089\/thy.2020.0276","article-title":"Safety and quality-of-Life data from an italian expanded access program of lenvatinib for treatment of thyroid cancer","volume":"31","author":"Giani","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0115","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fmed.2017.00220","article-title":"Lenvatinib-associated cervical artery dissections in a patient with radioiodine-refractory metastatic papillary thyroid carcinoma","volume":"4","author":"Groden","year":"2017","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0120","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1056\/NEJMc2023094","article-title":"Larotrectinib-enhanced radioactive iodine uptake in advanced thyroid cancer","volume":"383","author":"Groussin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0125","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bcp.12907","article-title":"Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer","volume":"81","author":"Gupta","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2020.03.003","article-title":"The efficacy of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma exhibiting primary resistance to front-line targeted therapy or immunotherapy","author":"Hamieh","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0135","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/1078-0432.CCR-14-3063","article-title":"Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma","volume":"21","author":"Hong","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0140","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s13318-017-0403-4","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of lenvatinib, an orally active, small-molecule, multitargeted tyrosine kinase inhibitor","volume":"42","author":"Hussein","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0145","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1574890110999150604114127","article-title":"Anti-VEGF anticancer drugs: mind the hypertension","volume":"9","author":"Katsi","year":"2014","journal-title":"Recent Adv. Cardiovasc. Drug Discov."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0150","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10928-010-9164-2","article-title":"A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080","volume":"37","author":"Keizer","year":"2010","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0155","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.seminoncol.2020.05.001","article-title":"Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: a systemic review","volume":"47","author":"Klajer","year":"2020","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0160","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/hr.2015.30","article-title":"Modulation of the QT interval duration in hypertension with antihypertensive treatment","volume":"38","author":"Klimas","year":"2015","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0165","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/bjc.2015.82","article-title":"Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors","volume":"112","author":"Kloth","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0170","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006502","article-title":"Signal transduction by vascular endothelial growth factor receptors","volume":"2","author":"Koch","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0175","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1186\/1471-2407-14-530","article-title":"Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib","volume":"14","author":"Koyama","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0180","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0185","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1742-7843.2010.00556.x","article-title":"Electrophysiological effects of the anti-cancer drug lapatinib on cardiac repolarization","volume":"107","author":"Lee","year":"2010","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0190","first-page":"381","article-title":"Use of rifampin in Haemophilus influenzae type b infections","volume":"140","author":"Li","year":"1986","journal-title":"Am. J. Dis. Child."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0195","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2174\/1568026620666200618113957","article-title":"Quinoline-based compounds with potential activity against drugresistant cancers","volume":"21","author":"Li","year":"2021","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1517\/17425255.3.1.81","article-title":"Transporter-mediated drug interactions: clinical implications and in vitro assessment","volume":"3","author":"Lin","year":"2007","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00105","article-title":"Response to entrectinib in differentiated thyroid cancer with a ROS1 fusion","author":"Liu","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2019.05.031","article-title":"Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy","volume":"118","author":"Locati","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0215","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/bdd.2204","article-title":"Minimal impact of hepatic and renal impairment on plasma protein binding of lenvatinib, and identification of its major plasma binding protein","volume":"40","author":"Mano","year":"2019","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0220","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2217\/fon-2019-0096","article-title":"Evaluation of the QTc interval during lenvatinib treatment in radioiodine-refractory differentiated thyroid cancer: reports from the real-life clinical practice","volume":"15","author":"Marina","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0225","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1089\/thy.2019.0221","article-title":"Efficacy and limitations of lenvatinib therapy for radioiodine-refractory differentiated thyroid cancer: real-world experiences","volume":"30","author":"Masaki","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0230","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.beem.2017.06.001","article-title":"Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: from the clinical trials to the real life","volume":"31","author":"Matrone","year":"2017","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0235","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0240","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Matsui","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0245","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00280-013-2339-y","article-title":"A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)","volume":"73","author":"Molina","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0250","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00280-015-2899-0","article-title":"A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors","volume":"76","author":"Nakamichi","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0255","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/bjc.2013.374","article-title":"Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer","volume":"109","author":"Nishio","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0260","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","article-title":"Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models","volume":"340","author":"Okamoto","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0265","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1021\/ml500394m","article-title":"Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization","volume":"6","author":"Okamoto","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0270","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1038\/s41598-019-41820-y","article-title":"Influence of CYP3A4\/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer","volume":"9","author":"Ozeki","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0275","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000491387","article-title":"Anti VEGF-TKI treatment and new renal adverse events not reported in phase III trials","volume":"7","author":"Paschke","year":"2018","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0280","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bcp.12387","article-title":"Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials","volume":"78","author":"Qi","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0285","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8834148","article-title":"Real-world data for lenvatinib in radioiodine-refractory differentiated thyroid cancer (RELEVANT): a retrospective multicentric analysis of clinical practice in Austria","volume":"2020","author":"Rendl","year":"2020","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109573","article-title":"The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells","volume":"70","author":"Roberts","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0295","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00228-014-1786-7","article-title":"Drug-drug interaction software in clinical practice: a systematic review","volume":"71","author":"Roblek","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0300","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc3078","article-title":"Chemotaxis in cancer","volume":"11","author":"Roussos","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103159","article-title":"A comprehensive review of feature based methods for drug target interaction prediction","volume":"93","author":"Sachdev","year":"2019","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0310","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0315","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40264-015-0300-1","article-title":"Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk\/benefit","volume":"38","author":"Shah","year":"2015","journal-title":"Drug Saf."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0320","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00280-014-2444-6","article-title":"Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers","volume":"73","author":"Shumaker","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0325","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40261-014-0217-y","article-title":"Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults","volume":"34","author":"Shumaker","year":"2014","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0330","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5414\/CP201937","article-title":"Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers","volume":"52","author":"Shumaker","year":"2014","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0335","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jcph.398","article-title":"Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration","volume":"55","author":"Shumaker","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0340","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cpdd.140","article-title":"Effects of ketoconazole on the pharmacokinetics of lenvatinib (E7080) in healthy participants","volume":"4","author":"Shumaker","year":"2015","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0345","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/14737140.2018.1524297","article-title":"Lenvatinib as a therapy for unresectable hepatocellular carcinoma","volume":"18","author":"Spallanzani","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0350","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RET-driven cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0355","doi-asserted-by":"crossref","DOI":"10.1177\/1073274818789361","article-title":"Lenvatinib: a promising molecular targeted agent for multiple cancers","volume":"25","author":"Suyama","year":"2018","journal-title":"Cancer Control"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0360","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/jcph.917","article-title":"Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses","volume":"57","author":"Tamai","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0365","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/638747","article-title":"Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models","volume":"2014","author":"Tohyama","year":"2014","journal-title":"J. Thyroid Res."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0370","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0375","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/1078-0432.CCR-10-2638","article-title":"Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors","volume":"17","author":"Yamada","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2021.103366_bib0380","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2045-824X-6-18","article-title":"Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage","volume":"6","author":"Yamamoto","year":"2014","journal-title":"Vasc Cell"},{"key":"10.1016\/j.critrevonc.2021.103366_bib0385","doi-asserted-by":"crossref","first-page":"44545","DOI":"10.18632\/oncotarget.10019","article-title":"Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis","volume":"7","author":"Zhu","year":"2016","journal-title":"Oncotarget"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821001542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821001542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:37:57Z","timestamp":1760902677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821001542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":77,"alternative-id":["S1040842821001542"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103366","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103366"}}